Oral semaglutide bioavailability optimization — meal timing evidence

james_edin said:

Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

FDA_TrackerJim said:

If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way.

Thank you for spelling out the reasoning rather than just the conclusion.

Adding the clinical framing, because it changes how the question reads. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

hans_munich said:

It helps to ask what evidence would change your mind before you look at any.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

Worth separating that from semaglutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Happy to go further on any of that.

Moderator note: the sourcing question belongs in the vendor section and has been split out. No action needed from anybody.